Among carcinomas, IGF-1R targeting has been most widely evaluated in breast, lung, colon, and pancreatic cancer and numerous reviews have outlined its impact, or absence thereof, in detail elsewhere. The gene discussed is IGF1R; the disease is carcinoma.